TOMI Environmental Solutions Expands Footprint in Cell and Gene Therapy Sector with Multi-Stage SteraMist iHP Implementation at a New Pharmaceutical Manufacturing Site

FREDERICK, Md., Dec. 22, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.^® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that a leading Cell and Gene Therapy (CGT) manufacturer has adopted SteraMist ionized Hydrogen Peroxide (iHP) technology for its commercial-scale facility. This multi-staged implementation strengthens the facility’s Contamination Control Strategy (CCS) to meet the rigorous current Good Manufacturing Practices (cGMP) requirements for developing novel genetic disease therapies.

The client has invested in multiple SteraMist systems to facilitate surface treatment and automated room fogging, ensuring the highest standards and safety. To provide a seamless transition to commercial production, the partnership includes TOMI’s comprehensive standard operating procedure (SOP) development package and Installation and Operational Qualification (IQ/OQ) package performed by the TOMI Qualification Team.

"This collaboration reflects the continued adoption of SteraMist iHP technology across the biopharmaceutical sector, particularly in the rapidly evolving Cell and Gene Therapy market," said James Cherrey, TOMI’s Director of Product Compliance and Manufacturing. “As CGT manufacturers transition from development to commercial-scale production, there is an increasing need for validated, scalable contamination control solutions. This multi-stage implementation demonstrates our ability to support that progression with a comprehensive, turnkey approach that aligns with cGMP requirements and long-term operational needs.”

To reset the laboratory space to an operational environment, TOMI’s iHP Corporate Service team will perform a comprehensive whole-facility fogging service. This service covers all critical areas, including manufacturing suites, quality control labs, and support spaces, ensuring the environment is sterile for critical pharmaceutical processes.

The rapid expansion of Cell and Gene Therapy and 503B compounding is driving a critical need for next-generation sterilization. TOMI remains at the forefront of this shift, providing specialized expertise and scalable solutions tailored to the stringent requirements of these high-growth sectors.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ:) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit  or contact us at .

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the life science sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:  

John Nesbett/Rosalyn Christian  

IMS Investor Relations